drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (TCR-T cell therapy)
drug_description
Autologous T cells engineered ex vivo to express an HPV-specific T-cell receptor and reinfused as monotherapy to target HPV antigen–expressing tumors via TCR–MHC engagement and cytotoxic T-cell effector functions.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an HPV-specific T-cell receptor that recognizes HPV-derived peptides presented by HLA/MHC on tumor cells; TCR–MHC engagement activates cytotoxic T-cell signaling, leading to perforin/granzyme-mediated lysis and cytokine-driven killing of HPV antigen–expressing cancer cells.
drug_name
SCG142 TCR-T cells
nct_id_drug_ref
NCT06544720